Nomogram predict relapse-free survival of patients with thymic epithelial tumors after surgery.
Adult
Aged
Biomarkers
Disease Management
Female
Follow-Up Studies
Humans
Leukocyte Count
Lymphocytes
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Neoplasms, Glandular and Epithelial
/ diagnosis
Neutrophils
Nomograms
Prognosis
ROC Curve
Retrospective Studies
Thymectomy
/ methods
Thymus Neoplasms
/ diagnosis
Treatment Outcome
Albumin
Nomogram
Overall survival
Ratio of neutrophils to lymphocytes
Thymic epithelial tumor
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
22 Jul 2021
22 Jul 2021
Historique:
received:
12
04
2021
accepted:
12
07
2021
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Hematological indicators and clinical characteristics play an important role in the evaluation of the progression and prognosis of thymic epithelial tumors. Therefore, we aimed to combine these potential indicators to establish a prognostic nomogram to determine the relapse-free survival (RFS) of patients with thymic epithelial tumors undergoing thymectomy. This retrospective study was conducted on 156 patients who underwent thymectomy between May 2004 and August 2015. Cox regression analysis were performed to determine the potential indicators related to prognosis and combine these indicators to create a nomogram for visual prediction. The prognostic predictive ability of the nomogram was evaluated using the consistency index (C-index), receiver operating characteristic (ROC) curve, and risk stratification. Decision curve analysis was used to evaluate the net benefits of the model. Preoperative albumin levels, neutrophil-to-lymphocyte ratio (NLR), T stage, and WHO histologic types were included in the nomogram. In the training cohort, the nomogram showed well prognostic ability (C index: 0.902). Calibration curves for the relapse-free survival (RFS) were in good agreement with the standard lines in training and validation cohorts. Combining clinical and hematologic factors, the nomogram performed well in predicting the prognosis and the relapse-free survival of this patient population. And it has potential to identify high-risk patients at an early stage. This is a relatively novel approach for the prediction of RFS in this patient population.
Sections du résumé
BACKGROUND
BACKGROUND
Hematological indicators and clinical characteristics play an important role in the evaluation of the progression and prognosis of thymic epithelial tumors. Therefore, we aimed to combine these potential indicators to establish a prognostic nomogram to determine the relapse-free survival (RFS) of patients with thymic epithelial tumors undergoing thymectomy.
METHODS
METHODS
This retrospective study was conducted on 156 patients who underwent thymectomy between May 2004 and August 2015. Cox regression analysis were performed to determine the potential indicators related to prognosis and combine these indicators to create a nomogram for visual prediction. The prognostic predictive ability of the nomogram was evaluated using the consistency index (C-index), receiver operating characteristic (ROC) curve, and risk stratification. Decision curve analysis was used to evaluate the net benefits of the model.
RESULTS
RESULTS
Preoperative albumin levels, neutrophil-to-lymphocyte ratio (NLR), T stage, and WHO histologic types were included in the nomogram. In the training cohort, the nomogram showed well prognostic ability (C index: 0.902). Calibration curves for the relapse-free survival (RFS) were in good agreement with the standard lines in training and validation cohorts.
CONCLUSIONS
CONCLUSIONS
Combining clinical and hematologic factors, the nomogram performed well in predicting the prognosis and the relapse-free survival of this patient population. And it has potential to identify high-risk patients at an early stage. This is a relatively novel approach for the prediction of RFS in this patient population.
Identifiants
pubmed: 34294070
doi: 10.1186/s12885-021-08585-y
pii: 10.1186/s12885-021-08585-y
pmc: PMC8299634
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
847Informations de copyright
© 2021. The Author(s).
Références
J Clin Oncol. 1999 Jul;17(7):2280-9
pubmed: 10561285
Lancet Oncol. 2015 Apr;16(4):e173-80
pubmed: 25846097
J Cardiothorac Surg. 2018 Nov 19;13(1):119
pubmed: 30454002
Mol Cancer. 2017 Aug 15;16(1):137
pubmed: 28810877
J Thorac Oncol. 2020 Mar;15(3):448-456
pubmed: 31726106
Lung Cancer. 2014 Feb;83(2):126-32
pubmed: 24377980
Lancet Oncol. 2018 Mar;19(3):382-393
pubmed: 29428165
J Clin Oncol. 2020 Sep 20;38(27):3233-3234
pubmed: 32701414
J Thorac Oncol. 2014 Dec;9(12):1810-5
pubmed: 25393794
Lancet Neurol. 2018 Apr;17(4):327-334
pubmed: 29553382
J Clin Oncol. 2017 Dec 20;35(36):4057-4065
pubmed: 28777690
J Thorac Oncol. 2010 Oct;5(10 Suppl 4):S304-12
pubmed: 20859124
Cancer Res Treat. 2018 Oct;50(4):1084-1095
pubmed: 29141396
Ann Thorac Surg. 2003 Sep;76(3):878-84; discussion 884-5
pubmed: 12963221
Ann Thorac Surg. 2019 May;107(5):1532-1539
pubmed: 30576633
Cancer. 2001 Jun 15;91(12):2214-21
pubmed: 11413508
J Clin Oncol. 2016 Jan 10;34(2):144-50
pubmed: 26503203
Clin Cancer Res. 2019 Jul 1;25(13):3839-3846
pubmed: 30967420
World J Surg. 2019 May;43(5):1370-1376
pubmed: 30719554
Ann Thorac Surg. 2013 Jan;95(1):299-303
pubmed: 23141529
JAMA Oncol. 2018 May 10;4(5):e175230
pubmed: 29372236
J Thorac Oncol. 2014 Sep;9(9 Suppl 2):S73-80
pubmed: 25396315
Mediators Inflamm. 2016;2016:8781740
pubmed: 27956763
Eur J Cardiothorac Surg. 2016 Feb;49(2):574-9
pubmed: 26547095
J Clin Oncol. 2017 Jun 20;35(18):1982-1990
pubmed: 28350520
World J Surg Oncol. 2017 Dec 2;15(1):214
pubmed: 29197400
J Thorac Oncol. 2014 May;9(5):596-611
pubmed: 24722150
Surg Today. 2018 Apr;48(4):422-430
pubmed: 29063371
J Clin Oncol. 2006 Aug 20;24(24):3819-20
pubmed: 16864852
Front Oncol. 2020 Apr 21;10:571
pubmed: 32373536
Ann Surg. 2017 Aug;266(2):339-345
pubmed: 27631774
Nat Commun. 2020 Aug 27;11(1):4308
pubmed: 32855399
Ann Thorac Surg. 2010 Apr;89(4):1071-7; discussion 1077-9
pubmed: 20338309